|Dr. Richard M. Glickman||Founder, Chairman, Pres & CEO||943.68k||N/A||1958|
|Mr. Michael R. Martin||Co-Founder & COO||333.34k||N/A||N/A|
|Mr. Dennis Bourgeault CPA, C.A.||CFO & Sec.||306.48k||N/A||N/A|
|Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C)||Exec. VP of Corp. Devel.||412.19k||N/A||N/A|
|Dr. Neil Solomons M.D.||Chief Medical Officer||466.61k||N/A||N/A|
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of April 1, 2019 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 1; Compensation: 8.